We are live on ! Find out more
ETNB

89bio
ETNB

Delisted

ETNB was delisted on the 29th of October, 2025.

Back to rankings

145 hedge funds and large institutions have $1.08B invested in 89bio in 2023 Q1 according to their latest regulatory filings, with 60 funds opening new positions, 47 increasing their positions, 30 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 20

122% more call options, than puts

Call options by funds: $55.5M | Put options by funds: $25M

83% more capital invested

Capital invested by funds: $590M → $1.08B (+$491M)

57% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 30

37% more funds holding

Funds holding: 106 → 145 (+39)

3.07% more ownership

Funds ownership: 99.58% → 102.65% (+3.1%)

Holders
145
Holders Change
+39
Holders Change %
+36.79%
% of All Funds
2.31%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.05%
New
60
Increased
47
Reduced
30
Closed
20
Calls
$55.5M
Puts
$25M
Net Calls
+$30.5M
Net Calls Change
+$25.5M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$38.7M
2
Janus Henderson Group
Janus Henderson Group
+$35.6M
3
RCM
RA Capital Management
Massachusetts
+$32.1M
4
Federated Hermes
Federated Hermes
Pennsylvania
+$30.7M
5
SCM
Suvretta Capital Management
New York
+$28.8M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$46.6M
2
DTC
Deep Track Capital
Connecticut
-$26.7M
3
CC
Commodore Capital
New York
-$9.65M
4
Walleye Capital
Walleye Capital
New York
-$6.11M
5
IC
Ikarian Capital
Texas
-$5.78M

ETNB Hedge Fund Activity: Q1 2023 in Review

145 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in 89bio (ETNB) for Q1 2023, worth a combined $1.08B — up 83% from $590M a quarter earlier.

Buyers outnumbered sellers: 60 funds opened new ETNB positions and 20 closed out — a net gain of 40 holders — while 47 added to existing stakes and 30 trimmed.

The largest buyer was State Street, adding an estimated $38.7M. The largest seller was OrbiMed, exiting entirely with an estimated $46.6M sold.

  • 145 institutional investors held 89bio (ETNB) as of Q1 2023, up from 106 in Q4 2022.
  • Funds reported $1.08B of 89bio stock for Q1 2023, up 83% quarter-over-quarter.
  • 60 funds opened new 89bio positions in Q1 2023 and 20 closed out, a net change of +40 holders.
  • The largest 89bio buyer in Q1 2023 was State Street, an estimated $38.7M added.
  • The largest 89bio seller in Q1 2023 was OrbiMed, an estimated $46.6M sold.

Based on aggregated 13F filings for Q1 2023.